SG11201903414SA - Crystalline form of (1r,2r)-2-[4-(3-methy1-1h-pyrazol-5-yl)benzoyl]-n-(4-oxo-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazin-3-yl)cyclohexanecarboxamide - Google Patents
Crystalline form of (1r,2r)-2-[4-(3-methy1-1h-pyrazol-5-yl)benzoyl]-n-(4-oxo-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazin-3-yl)cyclohexanecarboxamideInfo
- Publication number
- SG11201903414SA SG11201903414SA SG11201903414SA SG11201903414SA SG11201903414SA SG 11201903414S A SG11201903414S A SG 11201903414SA SG 11201903414S A SG11201903414S A SG 11201903414SA SG 11201903414S A SG11201903414S A SG 11201903414SA SG 11201903414S A SG11201903414S A SG 11201903414SA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- co7d
- tetrahydropyrazolo
- cyclohexanecarboxamide
- pyrazin
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/38—Nitrogen atoms
- C07D231/40—Acylated on said nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/44—Oxygen and nitrogen or sulfur and nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/44—Oxygen and nitrogen or sulfur and nitrogen atoms
- C07D231/46—Oxygen atom in position 3 or 5 and nitrogen atom in position 4
- C07D231/50—Acylated on said nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicinal Preparation (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662414109P | 2016-10-28 | 2016-10-28 | |
PCT/EP2017/077602 WO2018078097A1 (fr) | 2016-10-28 | 2017-10-27 | Forme cristalline de (1r,2r)-2-[4- (3-méthyl-1h-pyrazol-5-yl)benzoyl]-n-(4-oxo -4,5,6,7-tétrahydropyrazolo[1,5-a]pyrazin-3-yl)cyclohexanecarboxamide |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201903414SA true SG11201903414SA (en) | 2019-05-30 |
Family
ID=60387981
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201903414SA SG11201903414SA (en) | 2016-10-28 | 2017-10-27 | Crystalline form of (1r,2r)-2-[4-(3-methy1-1h-pyrazol-5-yl)benzoyl]-n-(4-oxo-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazin-3-yl)cyclohexanecarboxamide |
Country Status (17)
Country | Link |
---|---|
US (1) | US10689387B2 (fr) |
EP (1) | EP3532050B1 (fr) |
JP (1) | JP7041146B2 (fr) |
KR (1) | KR102509478B1 (fr) |
CN (1) | CN109890385B (fr) |
AU (1) | AU2017348598B2 (fr) |
CA (1) | CA3040341C (fr) |
CL (1) | CL2019000997A1 (fr) |
EA (1) | EA201990957A1 (fr) |
ES (1) | ES2933178T3 (fr) |
IL (1) | IL266031B (fr) |
MA (1) | MA46628A (fr) |
MX (1) | MX2019004574A (fr) |
MY (1) | MY188809A (fr) |
SG (1) | SG11201903414SA (fr) |
WO (1) | WO2018078097A1 (fr) |
ZA (1) | ZA201901093B (fr) |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL109254A (en) | 1993-04-29 | 1999-03-12 | Zeneca Ltd | History of the tetrahydropyran and tetrahydropuran site preparation and pharmaceutical preparations containing them |
US7977359B2 (en) * | 2005-11-04 | 2011-07-12 | Amira Pharmaceuticals, Inc. | 5-lipdxygenase-activating protein (FLAP) inhibitors |
GB2431927B (en) * | 2005-11-04 | 2010-03-17 | Amira Pharmaceuticals Inc | 5-Lipoxygenase-activating protein (FLAP) inhibitors |
EP2114876A4 (fr) * | 2007-02-05 | 2010-12-22 | Amira Pharmaceuticals Inc | Indoles inverses en tant qu'inhibiteurs de la protéine d'activation de la 5-lipoxygénase (flap) |
WO2009045700A2 (fr) * | 2007-10-05 | 2009-04-09 | Amira Pharmaceuticals, Inc. | Inhibiteurs de protéine activant la 5-lipoxygénase |
AU2009211215B2 (en) * | 2008-02-04 | 2011-11-03 | Astrazeneca Ab | Novel crystalline forms of 4- [4- (2-adamantylcarbam0yl) -5-tert-butyl-pyrazol-1-yl] benzoic acid |
AU2009325091A1 (en) * | 2008-05-23 | 2010-06-17 | Panmira Pharmaceuticals, Llc | 5-lipoxygenase-activating protein inhibitor |
TW201036957A (en) * | 2009-02-20 | 2010-10-16 | Astrazeneca Ab | Novel salt 628 |
AU2016258874B2 (en) * | 2015-05-04 | 2020-04-30 | Astrazeneca Ab | Pyrazole derivatives useful as 5-lipoxygenase activating protein (FLAP) inhibitors |
-
2017
- 2017-10-27 WO PCT/EP2017/077602 patent/WO2018078097A1/fr unknown
- 2017-10-27 MY MYPI2019002359A patent/MY188809A/en unknown
- 2017-10-27 CA CA3040341A patent/CA3040341C/fr active Active
- 2017-10-27 MX MX2019004574A patent/MX2019004574A/es unknown
- 2017-10-27 US US16/345,016 patent/US10689387B2/en active Active
- 2017-10-27 EP EP17800718.3A patent/EP3532050B1/fr active Active
- 2017-10-27 MA MA046628A patent/MA46628A/fr unknown
- 2017-10-27 ES ES17800718T patent/ES2933178T3/es active Active
- 2017-10-27 EA EA201990957A patent/EA201990957A1/ru unknown
- 2017-10-27 JP JP2019522887A patent/JP7041146B2/ja active Active
- 2017-10-27 AU AU2017348598A patent/AU2017348598B2/en active Active
- 2017-10-27 KR KR1020197014045A patent/KR102509478B1/ko active IP Right Grant
- 2017-10-27 CN CN201780065901.0A patent/CN109890385B/zh active Active
- 2017-10-27 SG SG11201903414SA patent/SG11201903414SA/en unknown
-
2019
- 2019-02-20 ZA ZA2019/01093A patent/ZA201901093B/en unknown
- 2019-04-12 CL CL2019000997A patent/CL2019000997A1/es unknown
- 2019-04-15 IL IL266031A patent/IL266031B/en active IP Right Grant
Also Published As
Publication number | Publication date |
---|---|
WO2018078097A1 (fr) | 2018-05-03 |
US20190276460A1 (en) | 2019-09-12 |
JP2019537586A (ja) | 2019-12-26 |
IL266031B (en) | 2021-05-31 |
CA3040341C (fr) | 2024-03-05 |
KR102509478B1 (ko) | 2023-03-10 |
ZA201901093B (en) | 2020-08-26 |
MX2019004574A (es) | 2019-08-21 |
AU2017348598A1 (en) | 2019-06-06 |
CA3040341A1 (fr) | 2018-05-03 |
MA46628A (fr) | 2019-09-04 |
CN109890385A (zh) | 2019-06-14 |
JP7041146B2 (ja) | 2022-03-23 |
MY188809A (en) | 2022-01-05 |
US10689387B2 (en) | 2020-06-23 |
EP3532050A1 (fr) | 2019-09-04 |
CL2019000997A1 (es) | 2019-06-21 |
AU2017348598B2 (en) | 2020-02-20 |
KR20190071757A (ko) | 2019-06-24 |
EA201990957A1 (ru) | 2019-09-30 |
EP3532050B1 (fr) | 2022-10-19 |
IL266031A (en) | 2019-06-30 |
ES2933178T3 (es) | 2023-02-02 |
CN109890385B (zh) | 2022-08-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201811414TA (en) | Heterocyclic compounds as immunomodulators | |
SG11201805300QA (en) | Heterocyclic compounds as immunomodulators | |
SG11201810600WA (en) | Fxr (nr1h4) modulating compounds | |
SG11201903155XA (en) | Pharmaceutical compounds | |
SG11201900349VA (en) | Somatostatin modulators and uses thereof | |
SG11201903487SA (en) | PROCESS FOR THE PREPARATION OF PYRAZOLO[1,5-a]PYRIMIDINES AND SALTS THEREOF | |
SG11201804152RA (en) | Heterocyclic compounds as immunomodulators | |
SG11201808566WA (en) | Polymorphic form of n-{6-(2-hydroxypropan-2-yl)-2-[2-(methylsulphonyl)ethyl]-2h-indazol-5-yl}-6-(trifluoromethyl)pyridine-2-carboxamide | |
SG11201805044WA (en) | Compounds useful as kinase inhibitors | |
SG11201811470PA (en) | Pyrazolopyrimidine derivatives as kinase inhibitor | |
SG11201900163PA (en) | Macrocycle kinase inhibitors | |
SG11201903483VA (en) | Compositions and methods for treating ezh2-mediated cancer | |
SG11201810965YA (en) | 1h-pyrazolo[4,3-b]pyridines as pde1 inhibitors | |
SG11201900558RA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
SG11201907356SA (en) | Piperidine-substituted mnk inhibitors and methods related thereto | |
SG11201906222WA (en) | Jak1 selective inhibitors | |
SG11201903061YA (en) | Combination treatments comprising administration of imidazopyrazinones | |
SG11201901048VA (en) | Pharmaceutical compositions and uses directed to lysosomal storage disorders | |
SG11201804587QA (en) | Isoindole compounds | |
SG11201809531SA (en) | BINDING MOLECULES SPECIFIC FOR FCγGAMMA RIIA AND USES THEREOF | |
SG11201811804QA (en) | Oxadiazolopyridine derivates for use as ghrelin o-acyl transferase (goat) inhibitors | |
SG11201811686UA (en) | 18f-labeled triazole containing psma inhibitors | |
SG11201809882XA (en) | Pharmaceutical combinations for treating cancer | |
SG11201903091VA (en) | Quinoxaline compounds as type iii receptor tyrosine kinase inhibitors | |
SG11201903795WA (en) | Salts of indazole derivative and crystals thereof |